{"name":"Cloudbreak Therapeutics, LLC","slug":"cloudbreak-therapeutics-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CBT-004","genericName":"CBT-004","slug":"cbt-004","indication":"Solid tumors (specific antigen target and indication under investigation in Phase 2)","status":"phase_2"},{"name":"CBT-001 single dose","genericName":"CBT-001 single dose","slug":"cbt-001-single-dose","indication":"Metastatic solid tumors","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"CBT-001","genericName":"CBT-001","slug":"cbt-001","indication":"Other","status":"phase_3"},{"name":"CBT-006","genericName":"CBT-006","slug":"cbt-006","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CBT-004","genericName":"CBT-004","slug":"cbt-004","phase":"phase_2","mechanism":"CBT-004 is a T cell engager designed to redirect patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.","indications":["Solid tumors (specific antigen target and indication under investigation in Phase 2)"],"catalyst":""},{"name":"CBT-001","genericName":"CBT-001","slug":"cbt-001","phase":"phase_3","mechanism":"CBT-001 is a therapeutic candidate in development by Cloudbreak Therapeutics, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"CBT-001 single dose","genericName":"CBT-001 single dose","slug":"cbt-001-single-dose","phase":"phase_2","mechanism":"CBT-001 is a small molecule that targets the CD47/SIRPα axis.","indications":["Metastatic solid tumors"],"catalyst":""},{"name":"CBT-006","genericName":"CBT-006","slug":"cbt-006","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPOURLUFZqLWVPQmg0ZkxkdnhlcW9Vcmw4bkhqa0UwckV6WmdhQVRrSkU2ZllQREJiamYwMGZ4LWpVNmR0MGlyUVFKb1RxMmlNZTRnVjNza0h6QTdNR3p4OUoyV2tZSy1vZHhqQXJHVTQ0RGxvbVVndzZQSm9jTVhTaUxJb3dodDhOaDJlVUppZVo4TjRRZG93djR0THpNY2xFOE05T0pGUEp2NUh3Rm9yTFA3cmlObUMxamUtSjZQTlRnYlI5aHZncTFtaFZxeWRjTHV4NmpIQmxFdGQ4a0MxczNBTUNUOWtJbG5xaDZkQkxJQWlOSGlLZW9zMFc4TlloNnpLc2NOZElOeTFkQ21Zb2t1Vmh1eVY4T3VmQnExYVBQc0lGa1ZEUkFHdGI5SkkwRHFz?oc=5","date":"2026-03-17","type":"trial","source":"Mena FN","summary":"Myopia Pipeline 2026: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Ziemer Group, NIDEK CO., LTD, 2Eyesvision, Carl Zeiss AG, Alcon, Coopervision, Topcon Healthcare - Mena FN","headline":"Myopia Pipeline 2026: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Ziemer Group, NIDEK CO., L","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxONHR0R3p3V01rUk5NdVZ5dXZELWZtUjRUc05lRTRLTXJUYVppYkFYOTZma29fZXZ6VHhZMHFTNnZ1ZUNfSDVScHNWdG81YWVESmE2VkdHTFlmVkZkVUhtVjN3WFVjQkVia09fc1Jicmc4MzdROC1LSG1HT2pWM0NRTi1LLXdrb29DMlRldkxyWUUxVlZDZHVucF9DZ2hWMmRpdzh5Mm9OSFc5cWJiYVhEelBvb0hQNy1kY2tSdnVFbw?oc=5","date":"2026-02-17","type":"regulatory","source":"Eyes On Eyecare","summary":"FDA clears Cloudbreak Pharma's IND for phase 2 presbyopia drop trials - Eyes On Eyecare","headline":"FDA clears Cloudbreak Pharma's IND for phase 2 presbyopia drop trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOUzRaR2NOR0NRd0JkLWN3aDBwWXBKU3AzRGlvVEFTS1pwM2U4c3ZQUVFDRlB4M21kZEhHNkRRalFYZjhHbFl2b090MEZycGI0My11bDIyLTBERDRyNVRHNF94bkJqeVZKalNIRXVhSWFWVFMzcmVpRzBkY0NpcWZkSjNFWkNEb29pdHc2RlpyNnVDX1dsRUI0OVJBOEZjeXhWV0p5UzE5M3gzM3liNmh4Rm16MUJwZTQ0VXV2d1ZOam5rU2NQcHNuTl9ZZ0tacF9TVmlnYg?oc=5","date":"2026-02-15","type":"regulatory","source":"TipRanks","summary":"Cloudbreak Pharma Wins FDA Green Light to Advance Presbyopia Drug CBT-199 Into Phase 2 - TipRanks","headline":"Cloudbreak Pharma Wins FDA Green Light to Advance Presbyopia Drug CBT-199 Into Phase 2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQekZCYzNmN2sxekhmWGItZlUtdXlPN1NaeG8yNVNGOFl6Si1nM1F5MHR4Q3ZRMTIwYnBFc1d2b3FXWVV6YUlQRElpQmowVC1DeV9EM0k2V21nYkE0Rk0xTTdXdzgwcUg3dWdfSm9IREtfNmxfTkhXMnV1Um16WnVDSmpacExGNzM2ejM5MW93bUd5T0lZVmpCdlpGTlFjUjRJai1wcEQ4UXRoVUNKY1pzTkZ6LVo4NWVGeVNhRExTeFY3MlFNVXRfQnBiUmRoWEltdUtmV25UVUtPMjI0cXM3UTE4YVRuWTdhMl9xcWZ0OE5aQUVWSFpKZWVYSFFNWDdNdlc1enFqVFhPQWUtSTJKUnRWOHhTaURraXhKeQ?oc=5","date":"2026-01-27","type":"trial","source":"GlobeNewswire","summary":"Cloudbreak Pharma Announces Successful End-of-Phase-2 - GlobeNewswire","headline":"Cloudbreak Pharma Announces Successful End-of-Phase-2","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUjNob29qXy0yZXFiZkJWdUQzdEhya3c1VHVyTk90RW1qY3piRXNfRThyTnZmdmU3Mzl5WFdab1EyWWhpMWZfdnhlQmQzOV9ka1dLTnVLemlGRXV2WG9wOHUwNmd4Y2FPdUVNUTVwZVoxN0hCWDFrdndyREpHRWY0Y3NVdC1DcVg5NEtDMENXTUxGVkhVREpiT2ZXLUtzNnIzYmZxYlJoTlhlejduWTh1eWVLYzFvQnpqMzN3?oc=5","date":"2024-04-08","type":"trial","source":"Fierce Pharma","summary":"Cloudbreak clears up truth of pterygium symptoms, treatment in survey of eye disease med trial volunteers - Fierce Pharma","headline":"Cloudbreak clears up truth of pterygium symptoms, treatment in survey of eye disease med trial volunteers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE9CT2syWENOWUh2MnFJX1V5OVVNbDJYZjUtcHkybVNHV2U2bUdINjQ3aEprVU13WW9uMnpHdFZYNmxaNzRmNHNSS2dTUGhJb2dLVGFYYy1XWDNPYlVacFdQVl9kWl9NNmY0M0FaaU1zM2lTc3hFcHc?oc=5","date":"2023-11-29","type":"patent","source":"Patently-O","summary":"Seeing Clearly: Article III Standing of IPR Judicial Review - Patently-O","headline":"Seeing Clearly: Article III Standing of IPR Judicial Review - Patently","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}